Lewy Body Dementia Market

DelveInsight's "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Lewy Body Dementia market report provides current treatment practices, emerging drugs, Lewy Body Dementia market share of the individual therapies, current and forecasted Lewy Body Dementia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Lewy Body Dementia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Lewy Body Dementia market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Lewy Body Dementia Disease Understanding and Treatment Algorithm

Lewy body dementia (LBD) is a disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain that act as messengers between brain cells (called neurotransmitters). Acetylcholine and dopamine are two such chemicals responsible for memory and cognition respectively. Lewy body dementia is one of the most common causes of dementia.

 

In the early stages of Lewy body dementia, the symptoms may be mild and as the disease advances, people with LBD require more help due to a decline in thinking and movement abilities. Symptoms of Lewy body dementia include visual hallucinations, unpredictable changes in concentration, attention, alertness, and wakefulness, muscle rigidity or stiffness, shuffling walk, slow movement, or frozen stance, problems with balance, stooped posture, loss of coordination, difficulty swallowing, weak voice, REM sleep behavior disorder, excessive daytime sleepiness Insomnia, restless leg syndrome, depression, anxiety, agitation, or restlessness, delusions, paranoia, changes in body temperature, problems with blood pressure, dizziness, fainting, sexual dysfunction, urinary incontinence, constipation and poor sense of smell.

 

While Lewy body dementia currently cannot be prevented or cured, some symptoms may respond to treatment for a period of time. A Lewy body dementia treatment plan involves medications, physical and other types of therapy, and counseling.

 

Lewy Body Dementia Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Lewy Body Dementia.

 

Lewy Body Dementia Treatment

It covers the details of conventional and current medical therapies available in the Lewy Body Dementia market for the treatment of the condition. It also provides Lewy Body Dementia treatment algorithms and guidelines in the United States, Europe, and Japan.

Lewy Body Dementia Epidemiology 

The Lewy Body Dementia epidemiology section provides insights about the historical and current Lewy Body Dementia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lewy Body Dementia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lewy Body Dementia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

Country Wise- Lewy Body Dementia Epidemiology

The epidemiology segment also provides the Lewy Body Dementia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Lewy Body Dementia Drug Chapters

The drug chapter segment of the Lewy Body Dementia report encloses the detailed analysis of Lewy Body Dementia marketed drugs and late-stage (Phase-III and Phase-II) Lewy Body Dementia pipeline drugs. It also helps to understand the Lewy Body Dementia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Lewy Body Dementia Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Lewy Body Dementia treatment.

 

Lewy body dementia Companies

  • Eli Lilly and Company
  • Axovant Sciences Ltd.
  • Sio Gene Therapies
  • Eisai Co., Ltd.
  • EIP Pharma Inc

 

Lewy body dementia Drugs

  • LY3154207
  • Nelotanserin
  • RVT-101
  • E2020
  • Donepezil
  • Neflamapimod

Lewy Body Dementia Market Outlook

The Lewy Body Dementia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Lewy Body Dementia market trends by analyzing the impact of current Lewy Body Dementia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Lewy Body Dementia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lewy Body Dementia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lewy Body Dementia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Lewy Body Dementia market in 7MM.

 

The United States Lewy Body Dementia Market Outlook

This section provides the total Lewy Body Dementia market size and market size by therapies in the United States.

 

EU-5 Countries: Lewy Body Dementia Market Outlook

The total Lewy Body Dementia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Lewy Body Dementia Market Outlook

The total Lewy Body Dementia market size and market size by therapies in Japan is also mentioned.

Lewy Body Dementia Drugs Uptake

This section focuses on the rate of uptake of the potential Lewy Body Dementia drugs recently launched in the Lewy Body Dementia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Lewy Body Dementia market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Lewy Body Dementia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Lewy Body Dementia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Lewy Body Dementia Pipeline Development Activities

The Lewy Body Dementia report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Lewy Body Dementia key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Lewy Body Dementia report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Lewy Body Dementia emerging therapies.

Reimbursement Scenario in Lewy Body Dementia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Lewy Body Dementia market trends, we take KOLs and SMEs ' opinion working in the Lewy Body Dementia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lewy Body Dementia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Lewy Body Dementia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Lewy Body Dementia Report

  • The report covers the descriptive overview of Lewy Body Dementia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Lewy Body Dementia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Lewy Body Dementia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Lewy Body Dementia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lewy Body Dementia market

Lewy Body Dementia Report Highlights

  • In the coming years, the Lewy Body Dementia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lewy Body Dementia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Lewy Body Dementia. The launch of emerging therapies will significantly impact the Lewy Body Dementia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lewy Body Dementia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Lewy Body Dementia Report Insights

  • Lewy Body Dementia Patient Population
  • Therapeutic Approaches
  • Lewy Body Dementia Pipeline Analysis
  • Lewy Body Dementia Market Size
  • Lewy Body Dementia Market Trends
  • Lewy Body Dementia Market Opportunities
  • Impact of upcoming Lewy Body Dementia Therapies

Lewy Body Dementia Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Lewy Body Dementia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Lewy Body Dementia Market
  • Lewy Body Dementia Drugs Uptake

Lewy Body Dementia Report Assessment

  • Current Treatment Practices
  • Lewy Body Dementia Unmet Needs
  • Lewy Body Dementia Pipeline Product Profiles
  • Lewy Body Dementia Market Attractiveness
  • Lewy Body Dementia Market Drivers
  • Lewy Body Dementia Maarket Barriers

Key Questions

Lewy Body Dementia Market Insights:

  • What was the Lewy Body Dementia drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Lewy Body Dementia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Lewy Body Dementia market size during the forecast period (2019-2032)?
  • At what CAGR, the Lewy Body Dementia market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Lewy Body Dementia market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Lewy Body Dementia market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Lewy Body Dementia Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Lewy Body Dementia?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Lewy Body Dementia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Lewy Body Dementia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lewy Body Dementia?
  • Out of all 7MM countries, which country would have the highest prevalent population of Lewy Body Dementia during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Lewy Body Dementia treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Lewy Body Dementia in the USA, Europe, and Japan?
  • What are the Lewy Body Dementia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Lewy Body Dementia?
  • How many therapies are in-development by each company for Lewy Body Dementia treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Lewy Body Dementia treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Lewy Body Dementia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lewy Body Dementia and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Lewy Body Dementia?
  • What are the global historical and forecasted market of Lewy Body Dementia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Lewy Body Dementia market
  • To understand the future market competition in the Lewy Body Dementia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lewy Body Dementia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Lewy Body Dementia market
  • To understand the future market competition in the Lewy Body Dementia market

1. Key Insights

2. Executive Summary of Lewy Body Dementia

3. Competitive Intelligence Analysis for Lewy Body Dementia

4. Lewy Body Dementia: Market Overview at a Glance

4.1. Lewy Body Dementia Total Market Share (%) Distribution in 2019

4.2. Lewy Body Dementia Total Market Share (%) Distribution in 2032

5. Lewy Body Dementia: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Lewy Body Dementia Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Lewy Body Dementia Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Lewy Body Dementia Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Lewy Body Dementia Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Lewy Body Dementia Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Lewy Body Dementia Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Lewy Body Dementia Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Lewy Body Dementia Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Lewy Body Dementia Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Lewy Body Dementia Treatment and Management

8.2. Lewy Body Dementia Treatment Algorithm

9. Lewy Body Dementia Unmet Needs

10. Key Endpoints of Lewy Body Dementia Treatment

11. Lewy Body Dementia Marketed Products

11.1. List of Lewy Body Dementia Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Lewy Body Dementia Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Lewy Body Dementia: Seven Major Market Analysis

13.1. Key Findings

13.2. Lewy Body Dementia Market Size in 7MM

13.3. Lewy Body Dementia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Lewy Body Dementia Market Outlook

15.1. United States: Lewy Body Dementia Market Size

15.1.1. Lewy Body Dementia Total Market Size in the United States

15.1.2. Lewy Body Dementia Market Size by Therapies in the United States

15.2. EU-5 countries: Lewy Body Dementia Market Size and Outlook

15.3. Germany Lewy Body Dementia Market Size

15.3.1. Lewy Body Dementia Total Market Size in Germany

15.3.2. Lewy Body Dementia Market Size by Therapies in Germany

15.4. France Lewy Body Dementia Market Size

15.4.1. Lewy Body Dementia Total Market Size in France

15.4.2. Lewy Body Dementia Market Size by Therapies in France

15.5. Italy Lewy Body Dementia Market Size

15.5.1. Lewy Body Dementia Total Market Size in Italy

15.5.2. Lewy Body Dementia Market Size by Therapies in Italy

15.6. Spain Lewy Body Dementia Market Size

15.6.1. Lewy Body Dementia Total Market Size in Spain

15.6.2. Lewy Body Dementia Market Size by Therapies in Spain

15.7. United Kingdom Lewy Body Dementia Market Size

15.7.1. Lewy Body Dementia Total Market Size in the United Kingdom

15.7.2. Lewy Body Dementia Market Size by Therapies in the United Kingdom

15.8. Japan Lewy Body Dementia Market Outlook

15.8.1. Japan Lewy Body Dementia Market Size

15.8.2. Lewy Body Dementia Total Market Size in Japan

15.8.3. Lewy Body Dementia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Lewy Body Dementia

17. KOL Views

18. Lewy Body Dementia Market Drivers

19. Lewy Body Dementia Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Lewy Body Dementia Epidemiology (2019-2032)

Table 2: 7MM Lewy Body Dementia Diagnosed and Treatable Cases (2019-2032)

Table 3: Lewy Body Dementia Epidemiology in the United States (2019-2032)

Table 4: Lewy Body Dementia Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Lewy Body Dementia Epidemiology in Germany (2019-2032)

Table 6: Lewy Body Dementia Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Lewy Body Dementia Epidemiology in France (2019-2032)

Table 8: Lewy Body Dementia Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Lewy Body Dementia Epidemiology in Italy (2019-2032)

Table 10: Lewy Body Dementia Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Lewy Body Dementia Epidemiology in Spain (2019-2032)

Table 12: Lewy Body Dementia Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Lewy Body Dementia Epidemiology in the UK (2019-2032)

Table 14: Lewy Body Dementia Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Lewy Body Dementia Epidemiology in Japan (2019-2032)

Table 16: Lewy Body Dementia Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Lewy Body Dementia Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Lewy Body Dementia Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Lewy Body Dementia Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Lewy Body Dementia Market Size in USD, Million (2019-2032)

Table 31: Spain Lewy Body Dementia Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Lewy Body Dementia Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Lewy Body DementiaMarket Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Lewy Body Dementia Epidemiology (2019-2032)

Figure 2: 7MM Lewy Body Dementia Diagnosed and Treatable Cases (2019-2032)

Figure 3: Lewy Body Dementia Epidemiology in the United States (2019-2032)

Figure 4: Lewy Body Dementia Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Lewy Body Dementia Epidemiology in Germany (2019-2032)

Figure 6: Lewy Body Dementia Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Lewy Body Dementia Epidemiology in France (2019-2032)

Figure 8: Lewy Body Dementia Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Lewy Body Dementia Epidemiology in Italy (2019-2032)

Figure 10: Lewy Body Dementia Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Lewy Body Dementia Epidemiology in Spain (2019-2032)

Figure 12: Lewy Body Dementia Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Lewy Body Dementia Epidemiology in the UK (2019-2032)

Figure 14: Lewy Body Dementia Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Lewy Body Dementia Epidemiology in Japan (2019-2032)

Figure 16: Lewy Body Dementia Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

Lewy body dementia Companies

  • Eli Lilly and Company
  • Axovant Sciences Ltd.
  • Sio Gene Therapies
  • Eisai Co., Ltd.
  • EIP Pharma Inc

Forward to Friend

Need A Quote